Holen Sie sich die Stockscreener-App
3.2484
1.85%
-0.0016
Schlusskurs vom Vortag:
$3.25
Offen:
$3.16
24-Stunden-Volumen:
1,917
Relative Volume:
0.10
Marktkapitalisierung:
$18.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.17M
KGV:
-0.1873
EPS:
-17.3434
Netto-Cashflow:
$-4.82M
1W Leistung:
-4.78%
1M Leistung:
-3.63%
6M Leistung:
+16.42%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.16
$3.30
1-Wochen-Bereich:
$3.1473
$3.50
52-Wochen-Spanne:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
3.1814 | 18.77M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
522.12 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.42 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.49 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newcelx Ltd Aktie (NCEL) Neueste Nachrichten
NewcelX Ltd (NCEL) Slides 2.87% to $3.38, Approaches Key Support at $3.21Mean Reversion Trade - siam.in
NewcelX (NCEL) Latest: Moves 3.18% Down to $3.26 in the Latest Session; the Near-Term Reference Band Stretches From $3.10 to $3.42 in Latest TradingPut Dominated - vinanet.vn
NewcelX Ltd (NCEL) Shareholders to Sell 694,000 Shares Amid Unpr - GuruFocus
NewcelX Ltd (NCEL) Pulls Back 2.54% as Shares Test Near-Term Support at $3.10Wyckoff Upthrust - vinanet.vn
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewcelX appoints diabetes researcher Ricordi to advisory board By Investing.com - Investing.com Nigeria
NewcelX (NCEL) Slides 6.2% to $3.34, Testing Key Support Near $3.17Wedge Breakout - dars.gov.et
NewcelX Ltd. (NCEL) Rises 3.83% to $3.49, Testing Key Resistance at $3.66Death Cross - vinanet.vn
Press Release: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - Moomoo
NewcelX Announces $1.4 Million Private Placement at 20% Premium to Market to Advance NCEL-101 for Type 1 Diabetes - Quiver Quantitative
NewcelX Prices $1.4 Million Premium Equity Financing to Advance Type 1 Diabetes Cell Therapy - TipRanks
NewcelX Ltd. (NCEL) Edges Higher as Stock Tests Key Resistance at $3.70Post-Earnings Moves - dars.gov.et
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Income Statement - TradingKey
NewcelX Ord Shs (NCEL) Balance Sheet - TradingKey
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NCEL|NewcelX Ord Shs|Price:3.755|Chg%:-0.070 - TradingKey
NewcelX Ord Shs (NCEL) Cash Flow - TradingKey
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NewcelX (NCEL) Secures Patent for Innovative Technology - GuruFocus
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio - The Manila Times
NewcelX Ltd. (NCEL) Holds Near $3.98 Support Zone After Modest DeclineRip Sell Trade - dars.gov.et
Laidlaw Initiates NewcelX(NCEL.US) With Buy Rating, Announces Target Price $23 - Moomoo
NCEL Initiated Coverage by Laidlaw & Co. -- Price Target Announced at $23 - GuruFocus
Laidlaw initiates NewcelX stock with buy rating on diabetes therapy - Investing.com
NLSP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NewcelX Strengthens Diabetes Push With Appointment of Leading Transplant Pioneer Camillo Ricordi - TipRanks
NewcelX appoints diabetes researcher Ricordi to advisory board - Investing.com
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - The Manila Times
NewcelX appoints diabetes research pioneer Dr. Camillo Ricordi to boost Type 1 diabetes therapy development. - Pluang
NewcelX Appoints Diabetes Research Leader Camillo Ricordi to Scientific Advisory Board Following FDA Pre-IND Milestone - Quiver Quantitative
Enterprise value to EBIT forward of NewcelX Ltd. – BOATS:NCEL - TradingView
Enterprise value to revenue forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Enterprise value to EBITDA forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NewcelX Ltd. announced that it has received $2.940234 million in funding - marketscreener.com
NCELNewcelX Ltd Volatility & Greeks - Finviz
NewcelX Ltd. (NCEL) Holds Steady at $3.85 as Traders Eye Key ResistanceInsider Buying Alerts - dars.gov.et
Price to book forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCEL Should I Buy - Intellectia AI
Newcelx Announces Successful FDA Pre-Ind Meet - Moomoo
NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials - The Globe and Mail
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - The Manila Times
NewcelX receives FDA feedback on type 1 diabetes therapy plan By Investing.com - Investing.com India
NewcelX Announces Successful FDA Pre-IND Meeting for NCEL-101 Type 1 Diabetes Program - Quiver Quantitative
NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes - marketscreener.com
NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting - TipRanks
Finanzdaten der Newcelx Ltd-Aktie (NCEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Newcelx Ltd-Aktie (NCEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Revel Michel | CSO and Director |
Apr 27 '26 |
Buy |
2.75 |
54,545 |
149,999 |
957,530 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):